[Amineptine: clinical review (author's transl)].
Amineptine is a new compound, derived from the tricyclic antidepressants. Its mechanism of action is principally dopaminergic and to a lesser extent serotoninergic. The following are here reported: The results of trials after a single dose: cerebral electrophysiology. Trials of treatment of depression--monopolar and bipolar,--involutional,--neurotic and reactive,--in chronic schizophrenia. The spectrum of activating antidepressant therapeutic activity of this drug is discussed. Other areas in which amineptine has seemed effective in children and adults are discussed. Finally, general, cardiac, ocular acceptability and tolerability in the elderly are reported, together with an analysis of cases of overdose.
D000275:Adjustment Disorders / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D002648:Child; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D003986:Dibenzocycloheptenes / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012894:Sleep Stages / Q000187:drug effects
D000929:Antidepressive Agents, Tricyclic; D003986:Dibenzocycloheptenes; C011597:amineptin
L'amineptine: synthèse des travaux cliniques.